Item type:Thesis, Open Access

Anwendbarkeit der Protonen-Magnetresonanzspektroskopie zur Bestimmung von chemotherapeutischen Arzneimitteln in der interventionellen Radiologie

Loading...
Thumbnail Image

Publisher

Supervisors

Item type:Person,

Abstract

With the help of the 7T Clinscan 70/30 USR Bruker, the measurement and evaluation of individual substances in native form, doxorubicin, 5-fluorouracil, gemcitabine, cytarabine, Embozene® and Lipiodol® is possible and can be carried out quickly and easily. The in vivo measurement of the cytostatic drugs used in the CAM model could be clearly localised and clearly distinguished from the surrounding tissue. The measured spectrum of the ex vivo pig liver is comparable with the measured spectrum of an in-vivo human liver. The visualisation of Lipiodol® and Doxorubicin + Embozene® in the ex vivo pig liver using proton magnetic resonance spectroscopy was successful. The substances measured here would theoretically be measurable if cytostatic drugs were applied locally using interventional methods in radiology (e.g. doxorubicin in the context of TACE). One possible problem could be the sometimes strong fluctuations in the signals sought and the associated increase in measurement deviations. This in turn could be solved by specially adapted programmes that reduce various interfering factors. The methodology should be usefully extended by potentially creating evaluation programmes that are designed not only for the evaluation of metabolites, but also for the substances to be measured. Standardised qualitative and quantitative measurement of the substances to be measured would thus theoretically be possible. If 1H-MRS is successfully implemented in the clinical field, improved therapy monitoring and thus individualised adjustment of the concentration of the cytostatic drug used could result in safer, more effective and more cost-effective patient treatment.

Review

Metadata

show more
Godzinski, Adam: Anwendbarkeit der Protonen-Magnetresonanzspektroskopie zur Bestimmung von chemotherapeutischen Arzneimitteln in der interventionellen Radiologie. : 2026-01-21.

License

Except where otherwised noted, this item's license is described as Attribution 4.0 International